Garret A. FitzGerald

Early life and education FitzGerald was born in Greystones, County Wicklow, on 11 May 1950.

FitzGerald was a member of the Science Board to the US Food and Drug Administration (FDA).

FitzGerald's work contributed substantially to the development of low-dose aspirin to prevent heart attacks and strokes. His work showing that selective COX-2 inhibitors depress the production of prostacyclin in the endothelium, thereby increasing cardiovascular risk, was instrumental in the withdrawal of Vioxx (rofecoxib) from the U.S. market in 2004. 2007 Cameron Prize for Therapeutics of the University of Edinburgh 2007 Honorary MD degree from Goethe University Frankfurt (Germany) 2011 Jakob Herz Prize 2012 Elected a Fellow of the Royal Society (FRS) 2012 Lucian Award 2013 Scheele Award 2013 Lefoulon-Delalande Prize 2013 Schottenstein Prize 2013 Honorary DSc degree from King's College London (United Kingdom) 2018 Elected to the German National Academy of Sciences 2019 Honorary Doctorate from the Royal College of Surgeons in Ireland 2021 Honorary Companion of the Order of St Michael and St George (CMG)